In 2002, the American College of Cardiology (ACC), the American Heart Association (AHA) and the National Heart, Lung and Blood Institute (NHLBI) issued a joint definition of rhabdomyolysis in connection with the use of statins and their toxicity. Rhabdomyolysis appeared to be characterized by muscular symptoms with a substantial elevation of creatine kinase, typically greater than 11 times the normal limit, together with kidney disease and, usually, with brown urine and myoglobinuria . Rhabdomyolysis is, more simply, a condition characterized by an injury or an insult to the skeletal muscle conditioning the release of the myocellular components , which leads to an increase in the blood levels of the intracellular components of the major muscles such as CK, aldolase, LDH, GOT, myoglobin, potassium, hyperuricaemia and hyperphosphatemia. As rhabdomyolysis is a potentially fatal condition, it requires rapid recognition and early treatment.
This is a preview of subscription content, log in to check access.
Pasternak RC, Smith SC Jr, Bairey-Merz CN et al (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke. 33(9):2337–2341CrossRefPubMedGoogle Scholar
Kasaoka S, Todani M, Kaneko T et al (2010) Peak value of blood myoglobin predicts acute renal failure induced by rhabdomyolysis. J Crit Care. 25(4):601–604CrossRefPubMedGoogle Scholar
Delaney KA, Givens ML, Vohra RB (2012) Use of Rifle criteria to predict the severity and prognosis of acute kidney injury in emergency department patients with rhabdomyolysis. J Emerg Med 42(5):521–528CrossRefPubMedGoogle Scholar